Patents Issued in June 30, 2020
  • Late stage addition of rheology modifier
    Patent number: 10695281
    Abstract: Methods of making personal care compositions, such as dentifrices, involving the addition of rheology modifiers at a later stage in the personal care composition formation process.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 30, 2020
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: Mark Lewis Agerton, Steven Robert Alexander, James Albert Berta, Gina Lynn Blum, Marco Caggioni, Susan Marie Dawes, David Michael Farren, Justin Thomas Lydon Hedin, Charles Phillip Miller, Christa Marie Novicki, Melissa Cherie Payne, Molly Rose Schottelkotte, John Christopher Wesner, Randall Lee Wood
  • Functionalized transition metal dichalcogenides and composition for antioxidation containing the same
    Patent number: 10695282
    Abstract: Disclosed is a method for synthesizing antioxidant materials based on transition metal dichalcogenide (TMD) compounds and a technology of preparing a composition using the same. The monolayer TMDs functionalized with an amphiphilic block polymer compound and which is stably dispersed in an aqueous solution are prepared by two methods. The thus prepared monolayer TMDs were proven to exhibit excellent and sustained antioxidant effects and excellent stability to light and heat.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 30, 2020
    Assignees: AMOREPACIFIC CORPORATION, INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Jin Nam, Jong-Ho Kim, Jin Woong Kim, Johnhwan Lee, Ji Eun Kim, Dabin Yim
  • Extract of and use thereof
    Patent number: 10695283
    Abstract: This invention relates to the isolation, and use of a plant extract in the treatment of skin hyper-pigmentation. More particularly, this invention relates to the isolation of a tyrosinase inhibitor in an extract of plant matehal from the Greyia radlkoferi (G. radlkoferi) plant, the extract including 5,7-dihidroxyflavone[(2S)-pinocembrin]; 2?,6?-dihydroxy-4?-methoxydihydrochalcone; 2?,4?,6?-trihydroxyhydrochalcone; 3,5,7-trihydroxyflavone and 4?,5?7-thhydroxyisoflavone.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 30, 2020
    Assignees: UNIVERSITY OF PRETORIA, UNIVERSITY OF KWAZULU-NATAL
    Inventors: Marco Nuno De Canha, Namrita Lall, Ahmed Hussein, Elizabeth Mogapi, Indres Moodley
  • Skin external composition for skin moisturization containing red yeast rice extract
    Patent number: 10695284
    Abstract: Disclosed herein is a skin external composition containing a red yeast rice extract. More particularly, disclosed is a skin external composition containing a red yeast rice extract which can increase the production of loricrin in keratinocytes and to strengthen the skin barrier function, thereby exhibiting an excellent effect of improving skin moisturization.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 30, 2020
    Assignee: Amorepacific Corporation
    Inventors: Dong Won Choi, Hong Guen Park, Han Byul Kim, Jin Sup Shim, In Hye Ha, Youn Joon Kim, Byung Young Kang
  • Anti-pollution complex comprising calendula extracts and an aqueous extract of lilum candidum bulb and uses thereof
    Patent number: 10695285
    Abstract: The invention relates to an anti-pollution complex comprising an aqueous extract of Calendula, an oily extract of Calendula and an aqueous extract of Lilium candidum, to a cosmetic topical composition comprising such an anti-pollution complex and to a cosmetic process to protect the skin from the harmful effects of pollution, in particular from the harmful effects of exhaust gases and heavy metals.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: June 30, 2020
    Assignee: MP2 COSMETIC SOLUTIONS SARL
    Inventor: Jacques Leclere
  • Dermocosmetic composition, production process of the topical composition, method for strengthening fragile nails and use of the composition
    Patent number: 10695286
    Abstract: The present invention relates to a dermocosmetic composition comprising natural substances for topical use, to improve the appearance, protection and strengthening of nails as well as assisting in the recovery of nail disorders. Additionally, the present invention also relates to a process for preparing said composition, a method for strengthening of fragile nails, and the use of this composition in the preparation of a topical composition for the treatment of nail disorders.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: June 30, 2020
    Assignee: BIOLAB SANUS FARMACÊUTICA LTDA
    Inventors: Dante Alário Junior, José Luiz Aiello Ritto
  • AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
    Patent number: 10695287
    Abstract: A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: June 30, 2020
    Assignee: CerSci Therapeutics, Inc.
    Inventors: Dennis I. Robbins, David H. Hitt, II
  • Reactive oxygen species (ROS)-responsive compositions and methods thereof
    Patent number: 10695288
    Abstract: A reactive oxygen species savaging emulsion; the emulsion comprising an injectable pharmaceutically acceptable composition and a polymeric poly(propylene sulfide) microsphere for targeted delivery to a site with elevated reactive oxygen species. In embodiments of the present invention, the microsphere is loaded with a biologically active agent.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 30, 2020
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, John R. Martin, Kristin P. O'Grady, Christopher E. Nelson
  • Zinc compositions for coated microneedle arrays
    Patent number: 10695289
    Abstract: A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 30, 2020
    Assignee: 3M Innovative Properties Company
    Inventors: Kenneth E. Brown, Daniel M. Dohmeier, Joan T. Moseman, Ying Zhang, Alan Harris, Gary Hattersley, Lisa A. Dick
  • Non-irritating, non-blurring, photostable ophthalmic sunscreen composition
    Patent number: 10695290
    Abstract: A non-irritation, non-blurring, photostable ophthalmic sunscreen composition contains at least one of the following: bemotrizinol; bisoctrizole; tris-biphenyl triazine; and/or octyl methoxycinnamate. A liquid vehicle base is then a remainder of the solution by weight. The composition is an artificial tear formulation or an ophthalmic suspension or ointment. The composition may include at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: June 30, 2020
    Assignee: A. EBBIE SOROUDI, M.D., M.S., A PROFESSIONAL MEDICAL CORPORATION
    Inventor: A. Ebbie Soroudi
  • Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
    Patent number: 10695291
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 30, 2020
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Chewing gum composition for use in alleviation of xerostomia induced by radiotherapy treatment
    Patent number: 10695292
    Abstract: The invention relates to a chewing gum composition for use in the alleviation of xerostomia induced by radiotherapy treatment, where the chewing gum composition comprises gum base and substantially no flavour ingredients. Moreover, the invention also relates to a dosage regimen for administering the chewing gum composition for use in alleviation of xerostomia induced by radiotherapy treatment. So in one embodiment of the invention the chewing gum composition is administered to a human subject before and/or during and/or after radiotherapy treatment.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 30, 2020
    Assignee: Fertin Pharma A/S
    Inventor: Heidi Ziegler Bruun
  • Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
    Patent number: 10695293
    Abstract: The present invention relates to a method of treating dermatitis, in particular radiation-induced dermatitis, with extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells. The present invention also provides a formulation comprising extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells, for use in the treatment of dermatitis, in particular radiation-induced dermatitis.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: June 30, 2020
    Assignee: Capricor, Inc.
    Inventors: Houman Hemmati, Luis Rodriguez-Borlado, Kiel A. Peck, Linda Marban
  • Porous silica material for use as a pharmaceutical or dietary active ingredient
    Patent number: 10695294
    Abstract: A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: June 30, 2020
    Assignee: Sigrid Therapeutics AB
    Inventors: Robert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett
  • Spray-dried pharmaceutical compositions comprising active agent nanoparticles
    Patent number: 10695295
    Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: June 30, 2020
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Maynard Emanuel Lichty, Garry T. Gwozdz
  • Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
    Patent number: 10695296
    Abstract: Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved stability of an active pharmaceutical ingredient, wherein the active ingredient comprises a compound of the formula: wherein X is N, Y is H or optionally substituted C1-C6 alkyl; R4 is morpholine optionally substituted with by C1-C6 alkyl; R7 is C1-C6 alkyl optionally substituted by one or more F; R8? is halogen; and R6 is wherein R10 is H, C1-C6 alkyl, halogen, CN or CF3; R12 is H or halogen; R13 is H, halogen or C1-C6 alkyl; and R17 is H, C1-C6 alkyl, (C1-C6 alkyl)-NH2; and, pharmaceutically acceptable salts and free bases thereof, wherein the active ingredient remains in substantially amorphous form after storage of the pharmaceutical formulation for a predetermined time and conditions.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: June 30, 2020
    Assignee: Asana BioSciences, LLC
    Inventors: Navnit Shah, Harpreet Sandhu, Ashish Chatterji, Helen Usansky, Louis Denis, Niranjan Rao, Sarper Toker
  • Tamper-resistant tablet providing immediate drug release
    Patent number: 10695297
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 30, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sebastian Schwier, Marcel Haupts, Udo Rüttgers, Lutz Barnscheid, Jana Denker
  • Abuse resistant forms of extended release hydromorphone, method of use and method of making
    Patent number: 10695298
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 30, 2020
    Assignee: INSPIRION DELIVERY SCIENCES, LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Disulfiram formulation
    Patent number: 10695299
    Abstract: Polymeric nanoparticles comprising disulfiram or derivatives thereof, and their use in the treatment of cancer.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: June 30, 2020
    Inventors: Weiguang Wang, Zhipeng Wang, Xiu-Wu Bian
  • Patch-type wound dressing comprising methylene blue mixture for treating skin wound
    Patent number: 10695300
    Abstract: There is provided a wound dressing prepared with a hydrocolloid gel, a polyurethane film, a PVA hydrogel, an alginate gel or the like, which has excellent stretchability and exudation absorbency of the wound surface for protection and prevention of infection on the wound surface in which continuity of a body tissue is destroyed by a physical impact or the like, can maintain a wet environment suitable for promoting healing of the wound surface, and has no pain or no worry to damage regenerated skin when the wound dressing is exchanged.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 30, 2020
    Assignee: D.R. NANO Co., Ltd.
    Inventor: Yong Deok Lee
  • Veterinary cannabinoid and menthol compositions and methods
    Patent number: 10695301
    Abstract: The present disclosure relates to compositions, including, hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol in a composition formulated to be administrable to a non-human animal rectally as a suppository.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: June 30, 2020
    Inventor: Babak Ghalili
  • Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
    Patent number: 10695302
    Abstract: The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 30, 2020
    Assignee: Drexel University
    Inventor: Sandhya Kortagere
  • Topical compositions and methods for making and using same
    Patent number: 10695303
    Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 30, 2020
    Assignee: Sebela Ireland Limited
    Inventors: Bhushan Hardas, Donna Dalton
  • Dosage forms and methods for enantiomerically enriched or pure bupropion
    Patent number: 10695304
    Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: June 30, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Supporting immunomodulatory agent
    Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Systems and methods for treating vitiligo
    Patent number: 10695306
    Abstract: The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: June 30, 2020
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10695307
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 30, 2020
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Inhalation formulations of treprostinil
    Patent number: 10695308
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: June 30, 2020
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Sustained-release liothyronine formulations, method of preparation and method of use thereof
    Patent number: 10695309
    Abstract: Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 30, 2020
    Assignee: WESTERN NEW ENGLAND UNIVERSITY
    Inventors: Shabnam N. Sani, Hamid Bakhteyar
  • D-serine treatment for neurological disorders that cause seizures
    Patent number: 10695310
    Abstract: Methods of treatment using D-serine to target brain cells expressing GluN3 subunit-containing triheteromeric NMDARs are disclosed. The methods include inhibiting calcium ion uptake by brain cells, treating epilepsy, and treating seizures by artificially administering D-serine.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 30, 2020
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: Sanjay S. Kumar
  • Solution for ophthalmology
    Patent number: 10695311
    Abstract: The invention relates to a solution for lysis of particles and fibers that adhere to a lens capsule of the eye during cataract operations, which solution contains 0.5-3.5 wt.-% lysine, particularly L-lysine, in an isotonic to hypertronic aqueous solution.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: June 30, 2020
    Inventor: Joerg H. Krumeich
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10695312
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 30, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Edible composition suitable for lowering serum cholesterol
    Patent number: 10695313
    Abstract: The present invention relates to an edible composition comprising plant sterol ester and/or plant stanol ester and triglyceride fat usable for lowering serum LDL cholesterol. The composition further comprises oligosaccharides and sugars. The composition can preferably be used in dietary supplements, fillings and toppings.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: June 30, 2020
    Assignee: RAISIO NUTRITION LTD
    Inventors: Päivi Kuusisto, Ingmar Wester
  • Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient
    Patent number: 10695314
    Abstract: The present invention relates to an antimicrobial composition comprising, as an active ingredient, 7,10-epoxyoctadeca-7,9-dienoic acid or a combination of 7,10-epoxyoctadeca-7,9-dienoic acid and another antibiotic. The growth of bacteria can be effectively inhibited regardless of the class of antibiotics when using the antimicrobial composition of the present invention. Therefore, the antimicrobial composition of the present invention can be useful in related pharmaceutical, food and cosmetic industries requiring the inhibition of bacterial growth.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: June 30, 2020
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Hak Ryul Kim
  • Composition comprising avermectin compounds without gelling agents
    Patent number: 10695315
    Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase, at least one fatty phase comprising one or more fatty compounds and at least one active phase comprising one or more active compounds chosen from avermectin compounds and one or more solvents and/or propenetrating agents of avermectin compounds, where the composition does not comprise gelling agent. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: June 30, 2020
    Assignee: NESTLÉ SKIN HEALTH S.A.
    Inventor: Claire Mallard
  • Methods of heating cannabis plant material
    Patent number: 10695316
    Abstract: The present invention includes a method of drying Cannabis plant material generally comprising exposing the Cannabis plant material to infrared radiation emitted from an infrared heater, such as a catalytic gas heater, the radiation having a wavelength of from about 3 to about 10 microns; and heating the Cannabis plant material to a temperature of from about 100° F. to about 400° F.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 30, 2020
    Assignees: Catalytic Industrial Group, Inc.
    Inventors: Virgil Macaluso, Corey Lowdon, Shih-Shin Chou
  • Composition for promoting production of brain-derived neurotrophic factor
    Patent number: 10695317
    Abstract: An object of the present invention is to provide novel composition and agent for promoting the production of a brain-derived neurotrophic factor (BDNF) and a novel method for promoting the production of BDNF. The present invention provides a composition for promoting the production of BDNF and an agent for promoting the production of BDNF, each comprising cacao polyphenols. The present invention also provides a method for promoting the production of BDNF, comprising feeding cacao polyphenols in a daily intake which is effective in promoting the production of BDNF for at least 2 weeks.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 30, 2020
    Assignee: Meiji Co., Ltd.
    Inventors: Midori Natsume, Yukio Ohshiba, Taketo Yamaji, Hiroyuki Ito, Toshihiko Osawa
  • Methods and compositions for improving cognitive function
    Patent number: 10695318
    Abstract: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 30, 2020
    Assignee: MARS, INCORPORATED
    Inventors: Stephen French, Amar P Inamdar, Ian Andrew MacDonald, Susan T Francis
  • Glucose conjugates of triptolide, analogs and uses thereof
    Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang
  • Compositions comprising urolithin compounds
    Patent number: 10695320
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 30, 2020
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Use of glycopyrrolate for treating tachycardia
    Patent number: 10695321
    Abstract: The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
    Type: Grant
    Filed: January 31, 2016
    Date of Patent: June 30, 2020
    Assignee: HEPTARES THERAPEUTICS LIMITED
    Inventors: Susan Snape, Robert Tansley
  • Inhibitors of bacterial growth
    Patent number: 10695322
    Abstract: New antimicrobials targeting L,D-transpeptidases, non-classical cysteine peptidases, have been developed and their unique chemical structures identified. Carbapenems and penems of the present invention are unique among ?-lactams as they acylate and inhibit L,D-transpeptidases, which likely results in their superior antimicrobial potency. These new antimicrobial agents can be used alone, or in combination with other classic antimicrobial agents that target D,D transpeptidases, when treating bacterial infections.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Rutgers, The State University of New Jersey
    Inventors: Gyanu Lamichhane, Craig A. Townsend, Evan Lloyd, Amit Kaushik, Pankaj Kumar, Joel Freundlich, Shaogang Li, Sean Ekins, Nicole Parrish
  • Compounds useful as kinase inhibitors
    Patent number: 10695323
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
    Patent number: 10695324
    Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 30, 2020
    Assignee: Washington University
    Inventors: Fumihiko Urano, Simin Lu
  • Compounds and methods for treating an epileptic disorder
    Patent number: 10695325
    Abstract: Provided, inter alia, are methods for treating an epilepsy disorder using clemizole, a clemizole analog, or pharmaceutical salts thereof.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: June 30, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Scott C. Baraban
  • Compositions and methods for treating or preventing dermal disorders
    Patent number: 10695326
    Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: June 30, 2020
    Assignee: Drexel University
    Inventors: Christian Sell, Timothy Nacarelli, Ashley Azar
  • Macrocyclic lactone compounds and methods for their use
    Patent number: 10695327
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
    Patent number: 10695328
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: June 30, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Amlodipine formulations
    Patent number: 10695329
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 30, 2020
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Methods of treatment
    Patent number: 10695330
    Abstract: This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: June 30, 2020
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Jason R. Harris